Stem cell transplantation modalities by randomization arm
| CR patients . | All patients (n = 254) . | Arm A (n = 133) . | Arm B (n = 121) . | P . |
|---|---|---|---|---|
| Patients with a donor*, n | ||||
| Sibling donor | 88 | 41 | 47 | |
| Unrelated donor | 81 | 46 | 35 | .39 |
| No donor | 85 | 46 | 39 | |
| SCT cohorts, n | ||||
| Allogeneic | 161 | 82 | 79 | |
| Autologous | 35 | 17 | 18 | .53 |
| No transplant | 58 | 34 | 24 | |
| Stem cell source type (allogeneic cohort), n | ||||
| Sibling donor | 76 | 33 | 43 | |
| Unrelated donor | 72 | 40 | 32 | .15 |
| Cord blood | 13 | 9 | 4 | |
| Conditioning type (allogeneic cohort), n | ||||
| MAC | 124 | 59 | 65 | .14 |
| RIC | 37 | 23 | 14 | |
| Median time from CR to SCT, d (range) | ||||
| Allogeneic SCT cohort | 105 (12-583)† | 106.5 (56-480) | 105 (12-583) | .69 |
| Autologous SCT cohort | 122 (69-312) | 125 (86-312) | 113.5 (69-286) | .28 |
| MMolR at MRD2 time point, n/tested | ||||
| Allogeneic SCT cohort | 90/134 | 51/71 | 39/63 | .27 |
| Autologous SCT cohort | 29/33 | 13/16 | 16/17 | .33 |
| Molecular CR at MRD2 time point, n/tested | ||||
| Allogeneic SCT cohort | 33/134 | 20/71 | 13/63 | .33 |
| Autologous SCT cohort | 15/33 | 9/16 | 6/17 | .30 |
| CR patients . | All patients (n = 254) . | Arm A (n = 133) . | Arm B (n = 121) . | P . |
|---|---|---|---|---|
| Patients with a donor*, n | ||||
| Sibling donor | 88 | 41 | 47 | |
| Unrelated donor | 81 | 46 | 35 | .39 |
| No donor | 85 | 46 | 39 | |
| SCT cohorts, n | ||||
| Allogeneic | 161 | 82 | 79 | |
| Autologous | 35 | 17 | 18 | .53 |
| No transplant | 58 | 34 | 24 | |
| Stem cell source type (allogeneic cohort), n | ||||
| Sibling donor | 76 | 33 | 43 | |
| Unrelated donor | 72 | 40 | 32 | .15 |
| Cord blood | 13 | 9 | 4 | |
| Conditioning type (allogeneic cohort), n | ||||
| MAC | 124 | 59 | 65 | .14 |
| RIC | 37 | 23 | 14 | |
| Median time from CR to SCT, d (range) | ||||
| Allogeneic SCT cohort | 105 (12-583)† | 106.5 (56-480) | 105 (12-583) | .69 |
| Autologous SCT cohort | 122 (69-312) | 125 (86-312) | 113.5 (69-286) | .28 |
| MMolR at MRD2 time point, n/tested | ||||
| Allogeneic SCT cohort | 90/134 | 51/71 | 39/63 | .27 |
| Autologous SCT cohort | 29/33 | 13/16 | 16/17 | .33 |
| Molecular CR at MRD2 time point, n/tested | ||||
| Allogeneic SCT cohort | 33/134 | 20/71 | 13/63 | .33 |
| Autologous SCT cohort | 15/33 | 9/16 | 6/17 | .30 |
Numbers of patients with a donor identified by the protocol criteria are shown; we used a 3-mo cutoff for identifying a donor and checked for each patient whether donor identification was obtained before this time cutoff.
Median time was 97.5 and 117 d in patients receiving SCT from sibling and unrelated donors, respectively.